Please wait while we open this resource.
K
Clinical reviews
BEYOND THE 4 PILLARS
Città della Salute e della Scienza Hospital, Turin, Italy
PDF4 pages1.7 MB
In heart failure with reduced ejection fraction (HFrEF), despite guideline-directed therapy, patients continue to experience significant residual risk. The foundational treatment pillars include ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. This document reviews the latest evidence regarding vericiguat, a novel treatment option, and its integration into contemporary HFrEF management, highlighting findings from recent clinical trials and meta-analyses.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology